TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search

ULTI

REX IncomeMax Option Strategy ETF

NASDAQETF
$10.47
-7.75%today

No SEC filings for this security

REX IncomeMax Option Strategy ETF is a foreign or OTC-listed security (NASDAQ) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$0.00 – $0.00
0.0052-week0.00
Volume
92.2K
1Y return
-34.40%
Beta
0.00

Price · 1Y

$10.47▼ -34.40%
over 1Y
L $9.30H $15.96

Recent news

market news →
Public Keys: Coinbase Cashes In, IBIT Slips, and REX Spins Volatility Into GoldBullish
finance.yahoo.com· 2025-11-01
Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical DevelopmentBullish
finance.yahoo.com· 2022-04-08
Ultimovacs ASA – Disclosure of voting rights of Annual General MeetingBullish
finance.yahoo.com· 2022-04-08
Ultimovacs to host Investor Days 2022: Meet the TeamBullish
finance.yahoo.com· 2022-03-30
Correction: Ultimovacs ASA: Annual Report 2021Bullish
finance.yahoo.com· 2022-03-25
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022Bullish
finance.yahoo.com· 2022-03-25
Ultimovacs ASA: Annual Report 2021Bullish
finance.yahoo.com· 2022-03-25
Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of MelanomaBearish
finance.yahoo.com· 2022-03-21

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.